Piroxicam

Piroxicam

SCHEMBL6942519

CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O.Cl

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Piroxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 5/20 0.98
PTGS2 known ✓ P35354 3/20 0.98
KDM4E B2RXH2 3/20 0.98
USP2 O75604 3/20 0.98
CYP2C9 P11712 2/20 0.98
CYP1A2 P05177 1/20 0.98
CYP3A4 P08684 1/20 0.98
CYP2D6 P10635 1/20 0.98
ALOX15 P16050 1/20 0.98
NFKB1 P19838 1/20 0.98
CYP2C19 P33261 1/20 0.98
BLM P54132 1/20 0.98
SLC22A6 Q4U2R8 1/20 0.98
SLC22A8 Q8TCC7 1/20 0.98
MAPK1 P28482 1/20 0.95
GAA P10253 1/20 0.68
LMNA P02545 2/20 0.66
KDR P35968 1/20 0.66
ABCB11 O95342 2/20 0.64
POLB P06746 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piroxicam SCHEMBL29396075 0.99 PTGS1 (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL29352427 0.99 PTGS1 (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL13462 0.99 PTGS1 (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL15741898 0.99 PTGS1 (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL28536166 0.99 PTGS1 (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL2680486 0.99 PTGS1 (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL6759456 0.98 KDM4E (1.00) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL5084571 0.98 PTGS1 (0.98) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL8908556 0.98 PTGS1 (0.98) PTGS1KDM4EUSP2PTGS2CYP2C9
Piroxicam SCHEMBL27394226 0.98 PTGS1 (0.98) PTGS1KDM4EUSP2PTGS2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118555971-A Amorphous photosensitive particles, methods of making and methods of using the same 马里兰大学帕克分校 2024-08-27 CN claimed
CN-112174966-B New method for preparing piroxicam hydrochloride 重庆圣华曦药业股份有限公司 2024-05-14 CN claimed
CN-118555971-A Amorphous photosensitive particles, methods of making and methods of using the same 马里兰大学帕克分校 2024-08-27 CN disclosed
CN-112384223-B Pharmaceutical composition containing poorly soluble basic agent 中外制药株式会社 2024-08-27 CN disclosed
CN-118320013-A Traditional Chinese medicine composition for preventing and treating diarrhea of piglets and preparation method thereof 北京生泰尔科技股份有限公司 2024-07-12 CN disclosed
CN-112174966-B New method for preparing piroxicam hydrochloride 重庆圣华曦药业股份有限公司 2024-05-14 CN disclosed
CN-112174966-B New method for preparing piroxicam hydrochloride 重庆圣华曦药业股份有限公司 2024-05-14 CN disclosed
CN-117903308-A Antagonistic anti-tumor necrosis factor receptor superfamily antibodies 综合医院公司 2024-04-19 CN disclosed
CN-115087488-A9 Antibodies and fusion proteins that bind CCR8 and uses thereof 震动疗法股份有限公司 2024-03-22 CN disclosed
CN-117425495-A Combination for the treatment of cancer 赛达克斯制药股份有限公司 2024-01-19 CN disclosed
CN-109476745-B Antagonistic anti-tumor necrosis factor receptor superfamily antibodies 综合医院公司 2023-11-24 CN disclosed
CN-112955179-A Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides 综合医院公司 2021-06-11 CN disclosed
CN-111989107-A Methods of treating cancer in pediatric patients 阿瑞雅德制药公司 2020-11-24 CN disclosed
CN-106536518-B Anthelmintic compounds 勃林格殷格翰动物保健美国公司 2020-05-12 CN disclosed
CN-1151161-C Nitrate salts of drugs ƿ�ӻ��� 2004-05-26 CN disclosed
US-6573252-B1 Therapy and prevention of bony disorders; improved gastrointestinal tolerability NICOX, S.A. (FR) 2003-06-03 US disclosed
EP-1100805-B1 MEDICINE NITRATE SALTS NICOX SA (FR) 2002-12-11 EP disclosed
CN-1310721-A Medicine nitrate salts NICOX SA (FR) 2001-08-29 CN disclosed
EP-1100805-A1 MEDICINE NITRATE SALTS NICOX S.A. (FR) 2001-05-23 EP disclosed
WO-2000006585-A1 MEDICINE NITRATE SALTS NICOX S.A. (FR) 2000-02-10 WO disclosed